Name: OCTREOTIDE (SandostatinR)
Classification: synthetic octapeptide analogue of naturally occurring somatostatin
  • inhibits pathologically increased secretion of peptides and serotonin produced within the gastroentero-pancreatic (GEP) endocrine system and growth hormone, thus used in pancreatitis or post pancreatic surgery to prevent complications such as pancreatic fistula or abscess
  • thought to reduce splanchnic blood flow primarily by inhibiting vasoactive gastrointestinal hormone secretion and exerting a direct vasomotor effect on splanchnic vessels, thus reducing portal blood flow;  used in the emergency management of bleeding gastroesophageal varices in patients with cirrhosis
  • for pancreatic effect: 100 ug sc tid
  • for bleeding esophageal varices:
    • 50 ug IV bolus
    • 50 ug/hr IV infusion for 24-48 hours
  • SC dose:  ensure site rotated with each dose
  • IV Bolus dose:
    • 50 ug in 50 ml NS over 10 minutes
  • IV Infusion:
    • 500 ug in 250 ml NS
Adverse Effects:


  • hyper- or hypo-glycemia
  • altered absoprtion of dietary fats
  • gallstones formation
  • nausea, vomiting, diarrhea, flatulence
  • pain or burning at sc administration site
  • flushing, edema
  • sinus bradycardia or conduction abnormalities
Drug Interactions:
  • oral cyclosporin + octreotide  = delayed and reduced absorption of cyclosporin
Monitoring Therapy:
  • blood glucose
  • amylase, lipase
  • bowel function
  • ECG, HR
  • BP
  • presence of hematemesis or melena
  • HgB
  • CCTC Protocol:
    • May be administered SC or by IV infusion by an RN.
    • Continuous infusion must be administered via an infusion pump. 

    Lynne Kelly, Pharmacist, CCTC
    Brenda Morgan, Clinical Nurse Specialist, CCTC
    Last Update: August 7, 2006

    LHSCHealth Professionals

    Last Updated March 24, 2009 | © 2007, LHSC, London Ontario Canada